Orexigen Therapeutics (OREX) Tops Q3 EPS by 78c, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Orexigen Therapeutics (OREX) Reports Commercialization & Distributorship Agreement with Merck (MRK) KGaA, Darmstadt, Germany for Contrave (naltrexone HCl / bupropion HCl extended release) in LatAM
November 13, 2017 8:11 AM ESTOrexigen Therapeutics, Inc. (NASDAQ: OREX) today announced that its wholly owned subsidiary, Orexigen Therapeutics Ireland Ltd., and Merck (NYSE: MRK) KGaA, Darmstadt, Germany have executed a distributorship agreement for Contrave® (naltrexone HCl / bupropion HCl extended release) in Latin America, including Brazil and Mexico. Under the terms of the agreement, Merck KGaA, Darmstadt, Germany will be responsible for all commercialization and regulatory activities and will own marketing authorization in the region. Orexigen will receive an upfront payment and other potential regulatory and sales milestones,... More
